127 related articles for article (PubMed ID: 27926898)
1. Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM; Ding Y; Kelly RP; Garhyan P; Shi C; Lim CN; Fu H; Watson DE; Lewin AJ; Landschulz WH; Deeg MA; Moller DE; Hardy TA
Diabetes Care; 2016 Nov; 39(11):e199-e200. PubMed ID: 27926898
[No Abstract] [Full Text] [Related]
2. Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Agrawal S; Gupta Y
Diabetes Care; 2016 Nov; 39(11):e198. PubMed ID: 27926897
[No Abstract] [Full Text] [Related]
3. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Kazda CM; Ding Y; Kelly RP; Garhyan P; Shi C; Lim CN; Fu H; Watson DE; Lewin AJ; Landschulz WH; Deeg MA; Moller DE; Hardy TA
Diabetes Care; 2016 Jul; 39(7):1241-9. PubMed ID: 26681715
[TBL] [Abstract][Full Text] [Related]
4. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
Guzman CB; Zhang XM; Liu R; Regev A; Shankar S; Garhyan P; Pillai SG; Kazda C; Chalasani N; Hardy TA
Diabetes Obes Metab; 2017 Nov; 19(11):1521-1528. PubMed ID: 28371155
[TBL] [Abstract][Full Text] [Related]
5. The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.
Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; Forman JL; Holst JJ; Knop FK; Vilsbøll T
Eur J Endocrinol; 2022 Oct; 187(4):507-518. PubMed ID: 35977072
[TBL] [Abstract][Full Text] [Related]
6. Efficient Synthesis of β-CF3/SCF3-Substituted Carbonyls via Copper-Catalyzed Electrophilic Ring-Opening Cross-Coupling of Cyclopropanols.
Li Y; Ye Z; Bellman TM; Chi T; Dai M
Org Lett; 2015 May; 17(9):2186-9. PubMed ID: 25885795
[TBL] [Abstract][Full Text] [Related]
7. Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
Bagger JI; Knop FK; Holst JJ; Vilsbøll T
Diabetes Obes Metab; 2011 Nov; 13(11):965-71. PubMed ID: 21615669
[TBL] [Abstract][Full Text] [Related]
8. Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus.
Grover S; Dhanjal JK; Goyal S; Grover A; Sundar D
BMC Bioinformatics; 2014; 15 Suppl 16(Suppl 16):S13. PubMed ID: 25521597
[TBL] [Abstract][Full Text] [Related]
9. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; van Hall G; Holst JJ; Knop FK; Vilsbøll T
Diabetes; 2020 Dec; 69(12):2619-2629. PubMed ID: 33004472
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, structure-activity relationships, and docking studies of pyrazole-containing derivatives as a novel series of potent glucagon receptor antagonists.
Shu S; Cai X; Li J; Feng Y; Dai A; Wang J; Yang D; Wang MW; Liu H
Bioorg Med Chem; 2016 Jun; 24(12):2852-63. PubMed ID: 27161876
[TBL] [Abstract][Full Text] [Related]
11. A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
Bergman A; Tan B; Somayaji VR; Calle RA; Kazierad DJ
Diabetes Res Clin Pract; 2017 Apr; 126():95-104. PubMed ID: 28237861
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.
Pettus JH; D'Alessio D; Frias JP; Vajda EG; Pipkin JD; Rosenstock J; Williamson G; Zangmeister MA; Zhi L; Marschke KB
Diabetes Care; 2020 Jan; 43(1):161-168. PubMed ID: 31694861
[TBL] [Abstract][Full Text] [Related]
13. Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).
Filipski KJ
Expert Opin Ther Pat; 2015 Jul; 25(7):819-30. PubMed ID: 25828189
[TBL] [Abstract][Full Text] [Related]
14. Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM; Ding Y; Kelly RP; Garhyan P; Shi C; Lim CN; Fu H; Watson DE; Lewin AJ; Landschulz WH; Deeg MA; Moller DE; Hardy TA
Diabetes Care; 2017 Jun; 40(6):808. PubMed ID: 28420698
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.
Kazierad DJ; Chidsey K; Somayaji VR; Bergman AJ; Calle RA
Diabetes Obes Metab; 2018 Nov; 20(11):2608-2616. PubMed ID: 29923286
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.
Xu G; Gaul MD; Song F; Du F; Liang Y; DesJarlais RL; DiLoreto K; Shook B; Rentzeperis D; Santulli R; Eckardt A; Demarest K
Bioorg Med Chem Lett; 2019 Oct; 29(20):126668. PubMed ID: 31519374
[TBL] [Abstract][Full Text] [Related]
17. The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.
Guzman-Perez A; Pfefferkorn JA; Lee EC; Stevens BD; Aspnes GE; Bian J; Didiuk MT; Filipski KJ; Moore D; Perreault C; Sammons MF; Tu M; Brown J; Atkinson K; Litchfield J; Tan B; Samas B; Zavadoski WJ; Salatto CT; Treadway J
Bioorg Med Chem Lett; 2013 May; 23(10):3051-8. PubMed ID: 23562063
[TBL] [Abstract][Full Text] [Related]
18. Glucagon receptor antagonists for the treatment of type II diabetes: current prospects.
Djuric SW; Grihalde N; Lin CW
Curr Opin Investig Drugs; 2002 Nov; 3(11):1617-23. PubMed ID: 12476962
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.
Xiong Y; Guo J; Candelore MR; Liang R; Miller C; Dallas-Yang Q; Jiang G; McCann PE; Qureshi SA; Tong X; Xu SS; Shang J; Vincent SH; Tota LM; Wright MJ; Yang X; Zhang BB; Tata JR; Parmee ER
J Med Chem; 2012 Jul; 55(13):6137-48. PubMed ID: 22708876
[TBL] [Abstract][Full Text] [Related]
20. Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.
Gumbiner B; Esteves B; Dell V; Joh T; Garzone PD; Forgie A; Udata C
Endocrine; 2018 Nov; 62(2):371-380. PubMed ID: 30203123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
